Gilead, Moderna, and Novavax have all enjoyed massive gains after announcing potential coronavirus drugs, leading their executives, scientists, and early investors to rake in millions. The profits come as global markets tank on growing coronavirus concerns. Moderna has gained the most of the three since Friday's close, jumping 60% after announcing on Monday it submitted the first coronavirus vaccine for human trials. Here are the seven shareholders to collectively profit $277 million from the surging biotech stocks. Visit the Business Insider homepage for more stories.